Tongfang Kontafarma Holdings Limited (1312.HK)
HKD 0.03
(-3.03%)
HKD 0.03
(-3.03%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 665.38 Million HKD | -30.99% |
| 2022 | 964.16 Million HKD | -21.03% |
| 2021 | 1.22 Billion HKD | 2.73% |
| 2020 | 1.18 Billion HKD | -42.84% |
| 2019 | 2.07 Billion HKD | 45.05% |
| 2018 | 1.43 Billion HKD | -10.16% |
| 2017 | 1.59 Billion HKD | 5.58% |
| 2016 | 1.51 Billion HKD | 47.96% |
| 2015 | 1.02 Billion HKD | 43.24% |
| 2014 | 713.02 Million HKD | 71.53% |
| 2013 | 415.68 Million HKD | -7.79% |
| 2012 | 450.78 Million HKD | -24.08% |
| 2011 | 593.73 Million HKD | -23.85% |
| 2010 | 779.68 Million HKD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 631.15 Million HKD | 0.0% |
| 2023 Q1 | 686.83 Million HKD | -28.76% |
| 2023 Q3 | 665.38 Million HKD | -3.12% |
| 2023 Q2 | 686.83 Million HKD | 0.0% |
| 2023 Q4 | 665.38 Million HKD | 0.0% |
| 2023 FY | 665.38 Million HKD | -30.99% |
| 2022 Q2 | 1.17 Billion HKD | 0.0% |
| 2022 FY | 964.16 Million HKD | -21.03% |
| 2022 Q4 | 964.16 Million HKD | 0.0% |
| 2022 Q3 | 964.16 Million HKD | -18.26% |
| 2022 Q1 | 1.17 Billion HKD | -3.39% |
| 2021 Q2 | 1.2 Billion HKD | 0.0% |
| 2021 Q1 | 1.2 Billion HKD | 1.73% |
| 2021 Q4 | 1.22 Billion HKD | 0.0% |
| 2021 FY | 1.22 Billion HKD | 2.73% |
| 2021 Q3 | 1.22 Billion HKD | 0.98% |
| 2020 Q2 | 2.35 Billion HKD | 0.0% |
| 2020 FY | 1.18 Billion HKD | -42.84% |
| 2020 Q3 | 1.18 Billion HKD | -49.56% |
| 2020 Q4 | 1.18 Billion HKD | 0.0% |
| 2020 Q1 | 2.35 Billion HKD | 13.33% |
| 2019 Q3 | 2.07 Billion HKD | 5.69% |
| 2019 Q2 | 1.96 Billion HKD | 0.0% |
| 2019 Q1 | 1.96 Billion HKD | 37.24% |
| 2019 Q4 | 2.07 Billion HKD | 0.0% |
| 2019 FY | 2.07 Billion HKD | 45.05% |
| 2018 Q4 | 1.43 Billion HKD | 0.0% |
| 2018 Q2 | 1.64 Billion HKD | 0.0% |
| 2018 FY | 1.43 Billion HKD | -10.16% |
| 2018 Q1 | 1.64 Billion HKD | 2.79% |
| 2018 Q3 | 1.43 Billion HKD | -12.6% |
| 2017 Q1 | 1.9 Billion HKD | 26.02% |
| 2017 Q4 | 1.59 Billion HKD | 0.0% |
| 2017 Q3 | 1.59 Billion HKD | -16.22% |
| 2017 FY | 1.59 Billion HKD | 5.58% |
| 2017 Q2 | 1.9 Billion HKD | 0.0% |
| 2016 Q2 | 1.08 Billion HKD | 1.8% |
| 2016 FY | 1.51 Billion HKD | 47.96% |
| 2016 Q3 | 1.51 Billion HKD | 39.6% |
| 2016 Q1 | 1.06 Billion HKD | 4.12% |
| 2016 Q4 | 1.51 Billion HKD | 0.0% |
| 2015 Q1 | 1.29 Billion HKD | 81.75% |
| 2015 Q4 | 1.02 Billion HKD | 1.92% |
| 2015 Q3 | 1 Billion HKD | -24.07% |
| 2015 Q2 | 1.31 Billion HKD | 1.85% |
| 2015 FY | 1.02 Billion HKD | 43.24% |
| 2014 Q4 | 713.02 Million HKD | 0.0% |
| 2014 Q3 | 713.02 Million HKD | 30.0% |
| 2014 Q1 | 548.49 Million HKD | 31.95% |
| 2014 FY | 713.02 Million HKD | 71.53% |
| 2014 Q2 | 548.49 Million HKD | 0.0% |
| 2013 Q2 | 406.57 Million HKD | 0.0% |
| 2013 Q4 | 415.68 Million HKD | 0.0% |
| 2013 Q3 | 415.68 Million HKD | 2.24% |
| 2013 FY | 415.68 Million HKD | -7.79% |
| 2013 Q1 | 406.57 Million HKD | -9.81% |
| 2012 Q3 | 450.78 Million HKD | -13.25% |
| 2012 Q2 | 519.61 Million HKD | 0.0% |
| 2012 Q4 | 450.78 Million HKD | 0.0% |
| 2012 FY | 450.78 Million HKD | -24.08% |
| 2011 Q4 | 593.73 Million HKD | 0.0% |
| 2011 FY | 593.73 Million HKD | -23.85% |
| 2010 FY | 779.68 Million HKD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -367.655% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 90.816% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -290.47% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | 6.238% |
| Qianhai Health Holdings Limited | 94 Million HKD | -607.838% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | 28.458% |
| Essex Bio-Technology Limited | 903.78 Million HKD | 26.377% |
| PuraPharm Corporation Limited | 689.65 Million HKD | 3.518% |
| SSY Group Limited | 4.49 Billion HKD | 85.194% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -81.427% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | 38.983% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 99.605% |